Stoke Therapeutics (NASDAQ:STOK) Receives “Buy” Rating from HC Wainwright

Share on StockTwits

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, AnalystRatings.com reports. They currently have a $30.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 3.52% from the company’s current price.

A number of other analysts also recently issued reports on STOK. JPMorgan Chase & Co. decreased their price objective on shares of Stoke Therapeutics from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, December 3rd. BTIG Research started coverage on shares of Stoke Therapeutics in a research note on Tuesday, November 12th. They issued a “buy” rating and a $46.00 target price on the stock. Cowen reiterated a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, August 15th. Finally, Zacks Investment Research raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a buy rating, Stoke Therapeutics presently has an average rating of “Buy” and an average price target of $35.17.

Shares of Stoke Therapeutics stock opened at $28.98 on Monday. Stoke Therapeutics has a 1 year low of $19.21 and a 1 year high of $39.04. The company’s fifty day simple moving average is $25.39.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.01. As a group, sell-side analysts predict that Stoke Therapeutics will post -2.08 earnings per share for the current year.

In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp sold 16,434 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $28.70, for a total value of $471,655.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 205,216 shares of company stock valued at $5,771,421 over the last three months.

Several institutional investors and hedge funds have recently bought and sold shares of STOK. Platinum Investment Management Ltd. bought a new stake in shares of Stoke Therapeutics in the second quarter valued at approximately $29,000. Strs Ohio purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at approximately $51,000. Victory Capital Management Inc. bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $73,000. Ladenburg Thalmann Financial Services Inc. bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $88,000. Finally, Morgan Stanley bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $104,000. Hedge funds and other institutional investors own 48.61% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Recommended Story: The risks of owning bonds

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.